{
  "docId": "019de075-e341-775b-a82c-decdaeb5c03e",
  "docSlug": "c5ed60c4cc85a094dbae2fa13cb26a34",
  "documentTitle": "Alkermes | Investor Presentation Deck | 37 slides",
  "authorId": "alkermes",
  "authorName": "Mural Oncology",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 37,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 32,
  "notes": "Includes a swimmer plot (left) and a summary table (right) with clinical trial metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/21",
  "deckHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e",
  "deckJsonHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json",
  "deckAnchorHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Swimmer plot showing duration of treatment for individual patients",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d74c510-20c5-4285-bb2a-f3948507a5d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.55,
        "y": 0.7
      },
      "kind": "list",
      "text": "All responders had been on prior CPI therapy and progressed; FDA Orphan Drug and Fast Track designations; Data supported design of ARTISTRY-6 study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81f1110b-05bd-403a-9cbe-3030cdd8b884",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Abbrev: adj: adjuvant; ATEZO: atezolizumab; BIN: binimetinib; CBP: carboplatin; CI: confidence interval; COB: cobimetinib; CPI: checkpoint inhibitor; CR: complete response; DAB: dabrafenib; DCR: disease control rate (CR+PR+SD); DOR: duration of response; ENCO: encorafenib; FDA: US Food and Drug Administration; IPI: ipilimumab; MV: melanoma vaccine; NA: not applicable; NIVO: nivolumab; ORR: overall response rate; PAC: paclitaxel; PD: progressive disease; PEMBRO: pembrolizumab; PR: partial response; SD: stable disease; TRAM: trametinib; TVEC: talimogene laherparepvec; VEM: vemurafenib",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "512f83a0-c810-49c8-8c23-0e7fdf19b830",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "table",
      "text": "Summary table of best overall response, ORR, DCR, and DOR",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12a20305-52aa-405a-bd89-bd675f6ccd10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ARTISTRY-1: IV Nemvaleukin Demonstrated Monotherapy Responses in Melanoma (Part B)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56c23cb2-00e8-40a2-916c-09f48477180d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 21,
      "from": 20,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "ba81daf0-fae5-4421-90e6-9efd4d2dbee9",
      "evidence": "Slides 20-21 present clinical results showing improved treatment outcomes with Nemvaleukin alfa.",
      "position": 1,
      "objective": "How does Nemvaleukin alfa improve treatment outcomes?",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}